77916-78-0

Basic information

• Product Name: 2-Methyl-3-phenyl-propylamine
• Synonyms: 2-Methyl-3-phenyl-propylamine;2-Methyl-3-phenyl-1-propanaMine;beta-Methylbenzenepropanamine
• CAS NO: 77916-78-0
• Molecular Formula: C₁₀H₁₅N
• Molecular Weight: 149.2328
• Mol File: 77916-78-0.mol
• Article Data: 7

Chemical Properties

• Boiling Point: 229.819°C at 760 mmHg
• Flash Point: 96.327°C
• Appearance: /
• Density: 0.937g/cm³
• Vapor Pressure: 0.068mmHg at 25°C
• Refractive Index: 1.522
• CAS DataBase Reference: 2-Methyl-3-phenyl-propylamine(CAS DataBase Reference)
• NIST Chemistry Reference: 2-Methyl-3-phenyl-propylamine(77916-78-0)
• EPA Substance Registry System: 2-Methyl-3-phenyl-propylamine(77916-78-0)

Safety Data

• HazardClass: IRRITANT
• Hazardous Substances Data: 77916-78-0(Hazardous Substances Data)

Usage

General Description

2-Methyl-3-phenyl-propylamine, also known as amphetamine, is a psychoactive stimulant and a substituted phenethylamine. It is primarily used for its stimulant effects, including increasing alertness, energy, and attention, as well as improving mood and providing a euphoric high when used recreationally. Amphetamine is a potent central nervous system stimulant that works by increasing the levels of certain neurotransmitters in the brain, particularly dopamine and norepinephrine, leading to its stimulating and mood-enhancing effects. It is commonly used in the treatment of attention-deficit hyperactivity disorder (ADHD), narcolepsy, and obesity, and it is also commonly abused for its euphoric effects. However, it can be addictive and has the potential for abuse and dependence, so it should be used carefully and only as prescribed by a healthcare professional.

InChI:InChI=1/C10H15N/c1-9(8-11)7-10-5-3-2-4-6-10/h2-6,9H,7-8,11H2,1H3

Upstream product

• 1611-02-5 2-cyano-3-oxo-3-phenyl-propionic acid ethyl ester 
• 117824-60-9 N-(2-Methyl-3-phenyl-propyl)-benzenesulfonamide 
• 117824-55-2 N-(2-Methyl-3-phenyl-propionyl)-benzenesulfonamide 
• 7499-19-6 2-methyl-2-phenylpropionamide 
• 786599-80-2 2-methyl-3-phenylpropylhydrazine 
• 5445-77-2 2-benzylpropionaldehyde 
• 1009-67-2 2-methyl-3-phenylpropanoic acid 

Downstream Products

• 111874-96-5 C-(3,4-Dichloro-phenyl)-N-(2-methyl-3-phenyl-propyl)-methanesulfonamide 
• 111875-06-0 2-(3,4-Dichloro-phenylmethanesulfonyl)-4-methyl-2,3,4,5-tetrahydro-1H-benzo[c]azepine 

Relevant articles and documents

SUBSTITUTED IMIDAZOLE CARBOXAMIDES AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS

The invention provides substituted imidazole carboxamides and related compounds, compositions containing such compounds, medical kits, and methods for using such compounds and compositions to treat a medical disorder, e.g., cancer, lysosomal storage disorder, neurodegenerative disorder, inflammatory disorder, in a patient.

Preparation of substituted enol derivatives from terminal alkynes and their synthetic utility

Stereodefined enol derivatives of aldehydes are prepared from terminal alkynes. Specifically, terminal alkynes are known to undergo Cp2ZrCl2-catalyzed methylalumination. Here, we show that the resultant vinylalanes can be oxygenated with peroxyzinc species to generate trisubstituted enolates. Electrophilic trapping with carboxylic anydrides or silyl triflates yields trisubstituted enol esters or silanes, respectively. The tandem carbometalation/oxygenation tolerates free and protected alcohols, heterocycles, olefins, and nitriles. Stereodefined enol esters can undergo asymmetric dihydroxylation to yield optically active α-hydroxy aldehydes. Reduction with NaBH4 provides the diols of 1,1-disubstituted olefins in excellent ee. An application of this methodology to the enantioselective synthesis of the insect pheromone frontalin is presented. Finally, α-hydroxy aldehydes are shown to undergo homologation to a terminal alkyne, reductive amination, oxidation and olefination. Preliminary results indicate that tandem carbometalation/amination can be accomplished with azodicarboxylates. In this way, ene-hydrazines are formed in excellent yield. Copyright

Substituted pyridine and pyridazine compounds and methods of use

Selected novel substituted pyridine and pyridazine compounds are effective for prophylaxis and treatment of diseases, such as TNF-α, IL-1β, IL-6 and/or IL-8 mediated diseases, and other maladies, such as cancer, pain and diabetes. The invention encompasses novel compounds, analogs, prodrugs and pharmaceutically acceptable salts thereof, pharmaceutical compositions and methods for prophylaxis and treatment of diseases and other maladies or conditions involving inflammation, cancer, pain, diabetes and the like. The subject invention also relates to processes for making such compounds as well as to intermediates useful in such processes.